Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of “Moderate Buy” by Analysts
Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given […]
6 Apr 03:48 · The Cerbat Gem